Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: Molecular bases for EGFR-targeted therapy

In Silico Analysis Validates Proteomic Findings of Formalin-fixed Paraffin Embedded Cutaneous Squamous Cell Carcinoma Tissue

“…AKT is a member of the phosphoinositide 3-kinase (PI3K)/AKT pathway and its activation in response to factors such as overexpression of EGF and its receptor (EGFR) has been reported during skin tumorigenesis (71)(72)(73)(74)(75). Interestingly, in line with previous studies (76), our IPA analysis predicted that EGF is activated in cSCC, which, together with the decrease in KRT10, suggest the potential role of the PI3K/AKT pathway in cSCC carcinogenesis.…”

Tumour–stroma crosstalk in the development of squamous cell carcinoma

“…These findings are supported by others that show sustained MMP-1 production requires autocrine EGFR activation (Ito, Nakajima et al 1995). Human SCC are known to often overexpress epidermal growth factor receptor (EGFR), and the up-regulation of EGFR correlates with increased cell motility and invasion in vitro, often associated with poor prognosis (Pilcher, Dumin et al 1999;Ali, Gunduz et al 2008;Uribe and Gonzalez 2011).…”

Expression of Tumor Necrosis Factor Receptor-associated Factor 6 in Lung Cancer Tissues

“…With the development of genomic and basic research, increasing numbers of cell molecular biomarkers have been considered as specific diagnosing and targeted therapeutic agents for lung cancer (Uribe and Gonzalez, 2011;Hirose et al, 2012;Brothers et al, 2013;Ramshankar and Krishnamurthy, 2013;Wang et al, 2013). However, clear molecular biomarkers for the clinical diagnosis and treatment of lung cancer have not been identified.…”